Cancer is a devastating disease whose incidence has increased in recent times and early detection can lead to effective treatment. Existing detection tools suffer from low sensitivity and specificity, and are high cost, invasive and painful procedures. Cancers affecting different tissues, ubiquitously express embryonic markers including Oct-4A, whose expression levels have also been correlated to staging different types of cancer. Cancer stem cells (CSCs) that initiate cancer are possibly the ‘transformed’ and pluripotent very small embryonic-like stem cells (VSELs) that also express OCT-4A. Excessive self-renewal of otherwise quiescent, pluripotent VSELs in normal tissues possibly initiates cancer. In an initial study on 120 known cancer patients, it was observed that Oct-4A expression in peripheral blood correlated well with the stage of cancer. Based on these results, we developed a proprietary HrC scale wherein fold change of OCT-4A was linked to patient status – it is a numerical scoring system ranging from non-cancer (0–2), inflammation (>2–6), high-risk (>6–10), stage I (>10–20), stage II (>20–30), stage III (>30–40), and stage IV (>40) cancers. Later the scale was validated on 1000 subjects including 500 non-cancer and 500 cancer patients. Ten case studies are described and show (i) HrC scale can detect cancer, predict and monitor treatment outcome (ii) is superior to evaluating circulating tumor cells and (iii) can also serve as an early biomarker. HrC method is a novel breakthrough, non-invasive, blood-based diagnostic tool that can detect as well as classify solid tumors, hematological malignancies and sarcomas, based on their stage.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
We have all the data and material available with us.
Clevers, H. (2011). The cancer stem cell: Premises, promises and challenges. Nature Medicine, 17(3), 313–319. https://doi.org/10.1038/nm.2304.
Batlle, E., & Clevers, H. (2017). Cancer stem cells revisited. Nature Medicine, 23, 1124–1134. https://doi.org/10.1038/nm.4409.
Ratajczak, M. Z., Ratajczak, J., & Kucia, M. (2019). Very small embryonic-like stem cells (VSELs): An update and future directions. Circulation Research, 124(2), 208–210. https://doi.org/10.1161/CIRCRESAHA.118.314287.
Bhartiya, D., Patel, H., Ganguly, R., Shaikh, A., Shukla, Y., Sharma, D., & Singh, P. (2018). Novel insights into adult and Cancer stem cell biology. Stem Cells and Development, 27(22), 1527–1539. https://doi.org/10.1089/scd.2018.0118.
Ratajczak, M. Z., Bujko, K., Mack, A., Kucia, M., & Ratajczak, J. (2019). Correction: Cancer from the perspective of stem cells and misappropriated tissue regeneration mechanisms (leukemia, (2018), 32, 12, (2519-2526), https://doi.org/10.1038/s41375-018-0294-7). Leukemia. https://doi.org/10.1038/s41375-019-0411-2.
Ratajczak, M. Z., Shin, D.-M., & Kucia, M. (2009). Very small embryonic/epiblast-like stem cells. A missing link to support the germline hypothesis of cancer development? American Journal of Pathology, 174(6), 1985–1992.
Ratajczak, M. Z., Shin, D.-M., Liu, R., Marlicz, W., Tarnowski, M., Ratajczak, J., & Kucia, M. (2010). Epiblast/germ line hypothesis of cancer development revisited: Lesson from the presence of Oct-4+ cells in adult tissues. Stem Cell Reviews and Reports, 6(2), 307–316.
Kaushik, A., Anand, S., & Bhartiya, D. (2020). Altered biology of testicular VSELs and SSCs by neonatal endocrine disruption results in defective spermatogenesis, reduced fertility and tumor initiation in adult mice. Stem Cell Reviews and Reports, 16(5), 893–908. https://doi.org/10.1007/s12015-020-09996-3.
Virant-Klun, I., Skerl, P., Novakovic, S., Vrtacnik-Bokal, E., & Smrkolj, S. (2019). Similar population of CD133+ and DDX4+ VSEL-like stem cells sorted from human embryonic stem cell, ovarian, and ovarian Cancer ascites cell cultures: The real embryonic stem cells? Cells, 8(7), 706. https://doi.org/10.3390/cells8070706.
Samardzija, C., Luwor, R. B., Volchek, M., Quinn, M. A., Findlay, J. K., & Ahmed, N. (2015). A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer. Molecular Cancer, 14(1), 152. https://doi.org/10.1186/s12943-015-0417-y.
Zhao, X., Lu, H., Sun, Y., Liu, L., & Wang, H. (2020). Prognostic value of octamer binding transcription factor 4 for patients with solid tumors: A meta-analysis. Medicine, 99(42), e22804. https://doi.org/10.1097/MD.0000000000022804.
Bhartiya, D., Shaikh, A., Nagvenkar, P., Kasiviswanathan, S., Pethe, P., Pawani, H., Mohanty, S., Rao, S. G. A., Zaveri, K., & Hinduja, I. (2012). Very small embryonic-like stem cells with maximum regenerative potential get discarded during cord blood banking and bone marrow processing for autologous stem cell therapy. Stem Cells and Development, 21(1), 1–6. https://doi.org/10.1089/scd.2011.0311.
Singh, P., & Bhartiya, D. (2020). Pluripotent stem (VSELs) and progenitor (EnSCs) cells exist in adult mouse uterus and show cyclic changes across estrus cycle. Reproductive Sciences, 28(1), 278–290. https://doi.org/10.1007/s43032-020-00250-2.
Palmirotta, R., Lovero, D., Cafforio, P., Felici, C., Mannavola, F., Pellè, E., Quaresmini, D., Tucci, M., & Silvestris, F. (2018). Liquid biopsy of cancer: A multimodal diagnostic tool in clinical oncology. Therapeutic Advances in Medical Oncology, 10, 175883591879463. https://doi.org/10.1177/1758835918794630.
Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., et al. (2008). Circulating mutant DNA to assess tumor dynamics. Nature Medicine, 14(9), 985–990. https://doi.org/10.1038/nm.1789.
Wagner, M., Yoshihara, M., Douagi, I., Damdimopoulos, A., Panula, S., Petropoulos, S., Lu, H., Pettersson, K., Palm, K., Katayama, S., Hovatta, O., Kere, J., Lanner, F., & Damdimopoulou, P. (2020). Single-cell analysis of human ovarian cortex identifies distinct cell populations but no oogonial stem cells. Nature Communications, 11(1), 1147. https://doi.org/10.1038/s41467-020-14936-3.
Karthaus, W. R., Hofree, M., Choi, D., Linton, E. L., Turkekul, M., Bejnood, A., Carver, B., Gopalan, A., Abida, W., Laudone, V., Biton, M., Chaudhary, O., Xu, T., Masilionis, I., Manova, K., Mazutis, L., Pe’er, D., Regev, A., & Sawyers, C. L. (2020). Regenerative potential of prostate luminal cells revealed by single-cell analysis. Science, 368(6490), 497–505. https://doi.org/10.1126/science.aay0267.
Bhartiya, D., & Sharma, D. (2020). Ovary does harbor stem cells-size of the cells matter! Journal of Ovarian Research, 13(1), 39. https://doi.org/10.1186/s13048-020-00647-2.
Mohammad, S. A., Metkari, S., & Bhartiya, D. (2020). Mouse pancreas stem/progenitor cells get augmented by Streptozotocin and regenerate diabetic pancreas after partial Pancreatectomy. Stem Cell Reviews and Reports, 16(1), 144–158. https://doi.org/10.1007/s12015-019-09919-x.
Kaushik, A., & Bhartiya, D. (2020). Additional evidence to establish existence of two stem cell populations including VSELs and SSCs in adult mouse testes. Stem Cell Reviews and Reports, 16(5), 992–1004. https://doi.org/10.1007/s12015-020-09993-6.
Shaikh, A., Anand, S., Kapoor, S., Ganguly, R., & Bhartiya, D. (2017). Mouse bone marrow VSELs exhibit differentiation into three embryonic germ lineages and Germ & Hematopoietic Cells in culture. Stem Cell Reviews and Reports, 13(2), 202–216. https://doi.org/10.1007/s12015-016-9714-0.
Shin, D. M., Zuba-Surma, E. K., Wu, W., Ratajczak, J., Wysoczynski, M., Ratajczak, M. Z., & Kucia, M. (2009). Novel epigenetic mechanisms that control pluripotency and quiescence of adult bone marrow-derived Oct4+ very small embryonic-like stem cells. Leukemia, 23(11), 2042–2051. https://doi.org/10.1038/leu.2009.153.
Bhartiya, D., Anand, S., Kaushik, A., & Sharma, D. (2019). Stem cells in the mammalian gonads. Advances in Experimental Medicine and Biology, 1201, 109–123.
Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013). Liquid biopsy: Monitoring cancer-genetics in the blood. Nature Reviews Clinical Oncology, 10(8), 472–484. https://doi.org/10.1038/nrclinonc.2013.110.
Shyamala, K., Girish, H., & Murgod, S. (2014). Risk of tumor cell seeding through biopsy and aspiration cytology. Journal of International Society of Preventive and Community Dentistry, 4(1), 5–11. https://doi.org/10.4103/2231-0762.129446.
Robertson, E. G., & Baxter, G. (2011). Tumour seeding following percutaneous needle biopsy: The real story! Clinical Radiology, 66(11), 1007–1014. https://doi.org/10.1016/j.crad.2011.05.012.
Holder, A. M., & Varadhachary, G. R. (2018). Cancer of unknown primary site. The MD Anderson Surgical Oncology Handbook, Sixth Edition, 44(9), 613–626.
Hawkey N.M., & Armstrong A.J. (2021). Liquid biopsy: It’s the bloody truth!. Clinical Cancer Research., clincanres.0531.2021
Yu, W., Hurley, J., Roberts, D., Chakrabortty, S. K., Enderle, D., Noerholm, M., Breakefield, X. O., & Skog, J. K. (2021). Exosome-based liquid biopsies in cancer: Opportunities and challenges. Annals of Oncology, 32(4), 466–477.
We would like to acknowledge Dr. AnantBhushan Ranade, Dr. Amit Bhatt and Dr. Rucha Dasare from Avinash Cancer Clinic for their generous support and for aiding in designing the clinical trial.
Ethics approval from Ethics Committee of Maharashtra Technical Education Society at Sanjeevan Hospital, Pune, India and was registered with Clinical Trial Registry India (CTRI/2019/01/017166).
Consent to Participate
Informed consent was obtained from all individual participants included in the study.
Consent for Publication
Patients signed informed consent regarding publishing their data.
Conflict of Interest
The HrC scale was co-developed by Epigeneres Biotech. The pilot clinical study was sponsored by Epigeneres Biotech. The IP for the technology is owned by 23Ikigai.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
• Cancers ubiquitously express embryonic marker Oct-4A, whose expression levels are related to stages of cancer.
• Cancer is initiated by the excessive self-renewal of very small embryonic-like stem cells (VSELs) that express Oct-4A.
• We developed a proprietary HrC scale wherein fold change of OCT-4A was linked to patient status.
• HrC scale can effectively screen, diagnose and prognose cancer with 100% sensitivity and specificity.
About this article
Cite this article
Tripathi, V., Bhartiya, D., Vaid, A. et al. Quest for Pan-Cancer Diagnosis/Prognosis Ends with HrC Test Measuring Oct4A in Peripheral Blood. Stem Cell Rev and Rep (2021). https://doi.org/10.1007/s12015-021-10167-1
- Cancer diagnosis